Dr Agarwals Healthcare IPO GMP Today, Date, Price, Subscription Status 

Dr Agarwals Healthcare IPO Overview

Kotak Mahindra Capital Company Limited, Morgan Stanley India Company Pvt Ltd, Jefferies India Private Limited, Motilal Oswal Investment Advisors Limited are the book running lead manager of the Dr Agarwals Healthcare IPO, while Kfin Technologies Limited is the registrar for the issue.

Refer to Dr Agarwals Healthcare IPO RHP for detailed information.

Dr Agarwals Healthcare IPO Important dates

Dr Agarwals Healthcare IPO opens on January 29, 2025, and closes on January 31, 2025.

Dr Agarwals Healthcare IPO Financial Performance

Dr Agarwals Healthcare IPO Key Performance Indicator

The market capitalization of Dr Agarwals Healthcare IPO is Rs 12698.37 Cr.

KPI as of Sun, Mar 31, 2024.

Dr Agarwals Healthcare IPO Objectives

The Company proposes to utilise the Net Proceeds from the Fresh Issue towards funding of the following objects:

1. Repayment/prepayment, in part or full, of certain of the borrowings and
2. General corporate purposes and unidentified inorganic acquisition.

Dr Agarwals Healthcare IPO Lot Size

Investors can bid for a minimum of 35 shares and in multiples thereof. The below table depicts the minimum and maximum investment by retail investors and HNI in terms of shares and amount.

Dr Agarwals Healthcare IPO Details

Dr Agarwals Healthcare IPO Company Overview and Services

Incorporated in 2010, Dr. Agarwal’s Health Care Limited offers a comprehensive range of eye care services, including cataract and refractive surgeries, consultations, diagnoses, non-surgical treatments, and the sale of optical products, contact lenses, accessories, and eye care-related pharmaceutical items.

As of September 30, 2024, there were 737 doctors providing care to patients across the company’s facilities. During this period, the company served 2.13 million patients and performed 220,523 surgeries. In the six months leading up to September 30, 2024, they served 1.15 million patients and conducted 140,787 surgeries.

The Services provided by the company are:-

Cataract surgeries Offer cataract surgical treatments at its Facilities, such as small incision cataract surgery, phacoemulsification, robotic cataract surgery and glued intraocular lens treatments;

Refractive surgeries: Refractive surgeries are procedures that correct eye refractive errors, helping individuals reduce or eliminate their need for glasses and contact lenses. The main types include LASIK, SMILE, implantable collamer lenses, and photorefractive keratectomy (PRK).

Other surgeries: Offer a range of other surgical treatments for eye ailments, such as surgical retinal treatments, corneal transplantation and pinhole pupilloplasty, oculoplasty and surgeries for the treatment of glaucoma and pterygium.

As of September 30, 2024, the company’s Indian network has 28 hubs (Tertiary Facilities, including three COEs) and 165 spokes (53 Primary and 112 Secondary Facilities).

As of September 30, 2024, the company has a presence in India across 117 metro and non-metro cities spanning 14 states and four union territories through 193 Facilities.

Competitive Strength

• Largest eye care services provider in India with a trusted brand
• End-to-end, comprehensive eye care services offering
• Scalable, asset-light, hub-and-spoke operating model
• Proven clinical excellence is driven by a strong clinical board and a history of surgical innovations.
• Doctor-promoters leading a team of qualified medical professionals and supported by experienced management
• Proven track record of delivering organic growth, integrating and scaling acquisitions and improving operating profitability

Dr Agarwals Healthcare IPO SWOT Analysis

Strengths

• Strong Brand Reputation: Dr. Agarwal’s is a well-established and recognized brand in the Indian eye care market, known for its quality services and experienced doctors.
• Large Network: The company has a wide network of clinics across India and internationally, providing easy access to patients.
• Experienced Management Team: The company is led by experienced professionals with a deep understanding of the healthcare industry.
• Growing Market: The Indian eye care market is expected to grow at a significant rate due to factors such as increasing prevalence of eye diseases, rising disposable incomes, and growing awareness of eye care.

Weaknesses

• High Debt Levels: The company has high levels of debt, which could increase its financial risk.
• Competition: The eye care market is becoming increasingly competitive with the entry of new players and existing players expanding their services.
• Dependence on Key Personnel: The company’s success depends heavily on its team of experienced doctors and surgeons.
• Regulatory Risks: The healthcare sector is subject to various regulations, which could impact the company’s operations.

Opportunities

• Expansion Plans: The company has plans to expand its network of clinics and increase its market share.
• Technological Advancements: The company can leverage technology to improve its services, such as telemedicine and artificial intelligence-powered diagnostics.
• Diversification: The company can diversify its revenue streams by offering new services and products.
• Mergers and Acquisitions: The company can acquire smaller players to expand its reach and gain access to new technologies.

Threats

• Economic Slowdown: An economic slowdown could impact consumer spending and reduce demand for elective medical procedures.
• Changes in Healthcare Policies: Changes in government policies could impact the profitability of the healthcare industry.
• Technological Disruptions: New technologies could disrupt the traditional healthcare delivery model.
• Reputational Risk: Negative publicity or incidents could damage the company’s reputation and impact patient trust.

Overall, Dr. Agarwal’s Healthcare has a strong brand and a good market position. However, the company faces challenges such as high debt levels and increasing competition. The success of the IPO will depend on the company’s ability to address these challenges and capitalize on the growth opportunities in the Indian eye care market.

Dr Agarwals Healthcare IPO GMP Details

Dr. Agarwal’s IPO last GMP is ₹32, last updated Jan 27th 2025 09:14 AM. With the price band of 402.00, Dr. Agarwal’s IPO’s estimated listing price is ₹434 (cap price + today’s GMP).The expected percentage gain/loss per share is 7.96%.>> Dr. Agarwal’s IPO Retail Subject to Sauda: ₹900>> Dr. Agarwal’s IPO Small HNI Subject to Sauda: ₹13500

We update GMP on a daily basis and based on last 4 sessions grey market activities, the current GMP (₹32) is showing signals towards the lower side. The lowest GMP is ₹30, while the highest GMP is ₹54. Stay with us to know the daily price trend of Dr. Agarwal’s IPO GMP with expected listing price.

GMP Date	IPO Price	GMP	Sub2 Sauda Rate	Estimated Listing Price	Last Updated
27-01-2025	402.00	₹32	900/13500	₹434 (7.96%)	27-Jan-2025
26-01-2025	402.00	₹32	900/13500	₹434 (7.96%)	27-Jan-2025
25-01-2025	402.00	₹30	800/12000	₹432 (7.46%)	26-Jan-2025
24-01-2025	402.00	₹54	1400/21000	₹456 (13.43%)	25-Jan-2025

Dr Agarwals Healthcare IPO Subscription Status 

Note that the bidding starts at 10 AM and ends at 5 PM on the days when the public issue is open.

Dr Agarwals Healthcare IPO Allotment status 

Dr Agarwals Healthcare IPO allotment is expected on Monday, February 3, 2025.

Dr Agarwals Healthcare IPO allotment status is not available at this time. Dr Agarwals Healthcare IPO – The allotment status will be available once the basis of allotment is finalized. Please revisit us to check the latest updates for Dr. Agarwal’s Health Care Limited IPO allotment status.

Dr Agarwals Healthcare IPO Contact Details

Dr. Agarwal’s Health Care Limited
1 st Floor, Buhari Towers
No.4, Moores Road, Off Greams Road,
Near Asan Memorial School, Chennai 600 006
Phone: +91 44 4378 7777
Email: secretarial@dragarwal.com
Website: https://dragarwals.co.in/

Disclaimer: Investing in Initial Public Offerings (IPOs) involves substantial risk, and financial returns are not guaranteed. The information provided should not be construed as financial or investment advice. Prospective investors are advised to consider their financial situation, investment objectives, and risk tolerance before participating in an IPO. It is recommended to consult with a qualified financial advisor or professional before making any investment decisions. Past performance is not indicative of future results. Investments in IPOs may be subject to market risk, including the potential loss of principal.

Want to Raise money for your company through SME IPO? Read More